Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

54.48USD
16 Feb 2018
Change (% chg)

$-0.37 (-0.67%)
Prev Close
$54.85
Open
$54.80
Day's High
$55.81
Day's Low
$54.29
Volume
405,159
Avg. Vol
404,285
52-wk High
$71.31
52-wk Low
$45.31

Chart for

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 2.38
Market Cap(Mil.): $8,225.50
Shares Outstanding(Mil.): 143.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

14 Feb 2018

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

09 Feb 2018

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

09 Feb 2018

BRIEF-Seattle Genetics Commences Tender Offer For Cascadian Therapeutics

* SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC.

08 Feb 2018

BRIEF-Seattle Genetics Announces Full Exercise Of Underwriters’ Option To Purchase Additional Shares

* SEATTLE GENETICS ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Source text for Eikon: Further company coverage:

02 Feb 2018

BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million

* SEATTLE GENETICS SAYS IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CASCADIAN THERAPEUTICS MAY BE REQUIRED TO PAY CO FEE OF $17 MILLION - SEC FILING Source text: (http://bit.ly/2E2RNXK) Further company coverage:

31 Jan 2018

BRIEF-Seattle Genetics Commences Underwritten Public Offering Of $550 Mln Of Shares

* SEATTLE GENETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

31 Jan 2018

BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics

* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE

31 Jan 2018

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)

09 Nov 2017

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

08 Nov 2017

Earnings vs. Estimates